- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00684541
Interpretation Modification Program for Social Phobia (SP Interp)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Social phobia is characterized by severe social anxiety leading to functional impairment (Schneider et al., 1992). Despite its high prevalence (13%, Kessler et al., 1994) over 30% of individuals with social anxiety who need treatment do not receive treatment (Olfson, et al., 2000) and 40% of individuals who present for treatment do not respond (39%, Heimberg, et al., 1998; 42%, Liebowitz et al., 2005). Thus, there is a clear need to develop highly effective and efficient treatments for GSP. Reducing negative interpretation of social events is an efficacious treatment for SP because:
- benign interpretations is associated with improvement in social anxiety after treatment (e.g., Franklin, Huppert, Langner, Leiberg, & Foa, 2005)
- negative interpretations are implicated in the pathogenesis of SP (e.g., Rapee & Heimberg, 1997)
- SPs have more negative interpretations of social events than non-anxious controls and individuals with other anxiety disorders (e.g., Amir et al, 1998)
- this bias ameliorates after successful treatment (e.g., Stopa & Clark, 2000).
Therefore, changing negative interpretations is an efficacious treatment for SP, and current cognitive-behavioral therapies use cognitive restructuring (CR) to target negative interpretations and replace them with more benign interpretations (Heimberg, et al., 1998). The goal of the current proposal is to test a new computerized treatment for SP that is designed to change negative interpretations. We chose a computerized intervention to increase efficiency and ease of delivery. We chose to test this intervention in GSP because interpretation bias is especially relevant to this clinical population. The long-term goal of this project is to improve service delivery using a widely available and economical intervention for GSP. More specifically, we will test three hypotheses in this proposal:
- Individuals with GSP completing the Interpretation Modification Program (IMP) will show a reduction in their negative interpretation
- Participants in the IMP will show a decrease in their social anxiety symptoms
- Change in social anxiety symptoms will be mediated by the change in interpretation scores, suggesting that interpretation change reduced social anxiety symptoms.
Pilot data (n=34) suggest that this intervention is efficacious. Thus, we aim to develop further and validate this highly efficient treatment for changing interpretations as a cost-effective treatment for patients with social phobia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92120
- San Diego State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Principle DSM-IV-TR (APA, 2000) Diagnosis of social phobia - Generalized Type (GSP)
Exclusion Criteria:
- No change in medication type or dosage twelve weeks prior to initiating treatment
- No current psychotherapy
- No evidence of suicidal intent
- No evidence of substance abuse in the last 6 months
- No evidence of current or past schizophrenia, bipolar disorder, or organic mental disorder
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interpretation Modification Program
The IMP procedure was identical to the word-sentence association paradigm (WSAP; Beard & Amir, 2009) except participants received feedback about their responses.
Participants received positive feedback when they endorsed benign interpretations or rejected threat interpretations of the ambiguous sentences on 100% of trials and negative feedback when they endorsed threat interpretations or rejected benign interpretations on 100% of trials.
This feedback manipulation was intended to reinforce a benign interpretation bias and extinguish the threat interpretation bias.
Participants completed two blocks of 110 training trials in each session.
Participants who completed Set A during the WSAP assessment saw Set B during the IMP and vice versa.
Each IMP session lasted approximately 20 min.
|
The IMP protocol includes twelve 30-min sessions delivered over a 6-week period.
Each session will comprise 220 trials.
In each trial, participants will first see either a non-threat or a threat (e.g.
"graceful" or "clumsy") word on the computer screen.
They will then see an ambiguous sentence (e.g.
"You dance at the party") and will be asked to indicate if the word and sentence were related by pressing a corresponding key.
Participants will receive positive feedback (i.e., "You are correct!") when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence.
Participants will receive negative feedback (i.e., "You are incorrect.")
when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence.
|
Placebo Comparator: Interpretation Control Condition
The ICC was identical to the IMP, except that participants received positive feedback when they endorsed threat interpretations on half (50%) of the trials and negative feedback when they endorsed threat interpretations for the remaining half (50%) of trials.
This frequency was the same for benign interpretations.
Thus, the control group was reinforced equally for making threat and benign interpretations.
The ICC was not intended to change interpretation significantly in either direction.
|
Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed.
Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Liebowitz Social Anxiety Scale (LSAS)
Time Frame: Pre, Post (6 weeks), Followup (3 months after post-assessment)
|
Our primary outcome measure was the clinician-administered LSAS (Liebowitz, 1987), a 24-item scale that provides separate scores for fear and avoidance of social interaction and performance situations.
LSAS scores range from 0 to 144.
The LSAS has strong psychometric properties (Heimberg et al., 1999) and is arguably the gold-standard outcome measure in treatment research in SAD (e.g., Clark et al., 2006; Heimberg et al., 1998).
Higher scores indicate more severe symptoms.
|
Pre, Post (6 weeks), Followup (3 months after post-assessment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Social Phobia and Agoraphobia Inventory
Time Frame: Pre, Post (6 weeks), Followup (3 months after post-assessment)
|
Our secondary outcome assessment of social anxiety symptoms was the Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel, Dancu, & Stanley, 1989), a 45-item self-rated measure that assesses the cognitive, behavioral, and somatic dimensions of SAD.
SPAI scores range from 45 to 315, with higher scores indicating more severe symptoms.
Previous research suggests that the SPAI has sound psychometric properties (e.g., Turner et al., 1989).
Internal consistencies for these measures in the current sample were satisfactory.
|
Pre, Post (6 weeks), Followup (3 months after post-assessment)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nader Amir, Ph.D., SDSU/UCSD
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1-Amir
- 5R34MH073004-03 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Social Anxiety Disorder
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
Tel Aviv UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)Israel
-
University of BernUniversity of LuebeckActive, not recruitingSocial Anxiety Disorder (Social Phobia)Switzerland
-
Aya Technologies LimitedCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder (Social Phobia)United Kingdom
-
Daniel LiebermanTerminatedAnxiety | Anxiety Disorder SocialUnited States
-
Weill Medical College of Cornell UniversityBrain & Behavior Research FoundationTerminatedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Tufts UniversityCompletedSocial Anxiety | Social Anxiety Disorder | Social Anxiety Disorder of ChildhoodUnited States
-
Sumitomo Pharma America, Inc.BehaVR LLCCompletedSocial Anxiety Disorder (SAD)United States
-
Emory UniversityBristol-Myers SquibbCompleted
-
Florida International UniversityYale UniversityRecruitingSocial Anxiety Disorder of ChildhoodUnited States
Clinical Trials on Interpretation Modification Program
-
Ryerson UniversityCompleted
-
Universidad Complutense de MadridCompletedDepression | Cognitive ChangeSpain
-
University of DenverNational Institute of Mental Health (NIMH); University of California, Los AngelesCompletedAnxiety DisordersUnited States
-
University of SouthamptonEconomic and Social Research Council, United KingdomCompletedChronic Pain | Musculoskeletal Pain DisorderUnited Kingdom
-
Brown UniversityNational Institute of Mental Health (NIMH); Memorial Hospital of Rhode Island; Mclean HospitalCompletedAnxiety DisordersUnited States
-
University of Wisconsin, MilwaukeeCompletedObsessive-Compulsive DisorderUnited States
-
Florida State UniversityCompletedBody Dysmorphic DisorderUnited States
-
Florida State UniversityCompleted
-
University of VirginiaCompleted
-
Mclean HospitalRecruitingObsessive-Compulsive DisorderUnited States